12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcetris brentuximab vedotin: Interim Phase II data

Interim data from 16 evaluable patients with relapsed CD30-positive CTCL in an investigator-sponsored, open-label, U.S. Phase II trial showed that 1.8 mg/kg IV Adcetris given every 3 weeks produced 12 partial responses plus 3 cases of stable disease. Additionally, 68% of patients maintained response at week 25. Median duration of response has not yet been reached. Seattle Genetics also said median CD30 expression on lymphoid cells in biopsies of skin lesions was 15% and that clinical activity was not dependent on CD30 expression levels. The most...

Read the full 406 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >